Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021 Posted byZacks Equity Research December 13, 2021 Leave a comment on Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021 Angion’s (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.